Receptor Therapeutics Inc. – a MaRS tenant – has raised $500,000 from the OICR’s IPDC Program via its OncoTek Drug Delivery Inc. subsidiary.

The funds will be used to drive the preclinical development of the company’s PoLi-PTX technology – a drug delivery system for intraperitoneal ovarian cancer.  PoLi-PTX is intended to permit effective localized cancer therapy without the associated side-effects of traditional chemotherapy.

Read the news release here (PDF).

Congratulations!

John McCulloch

John provides assistance to life sciences entrepreneurs in business strategy, management, intellectual property, financing and licensing. See more…